Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

Patients with actionable genomic alterations were previously treated with an approved targeted therapy and platinum ... as a monotherapy and in combination with other anticancer treatments in various ...

Aileen Lamb, from Edinburgh who had acute myeloid leukaemia said the approval of the new drug gives sufferers hope.

An obvious next step in the development and growth of CAR T-cell therapies has been the jump to solid tumors. Because of ...

AstraZeneca and Daiichi Sankyo have claimed approval in the EU for Enhertu as a second-line therapy for HER2-positive ... to-be-filed new indication as a combination with Herceptin in HER2 ...

The results suggest that AZ and Daiichi Sankyo could be in line for ... Gilead is also testing its drug as a first-line therapy for NSCLC in combination with Keytruda in a trial sponsored by ...

The approval of Yescarta means more patients in Scotland can be treated with CAR-T therapy sooner - giving people like ... and get the latest news sent straight to your messages. Daiichi Sankyo’s drug ...

AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application ... including an EGFR-directed therapy. The companies have voluntarily withdrawn the BLA in the US for ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...